Capan-2 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Pancreas cancer cell lines |
| Organism |
Human |
| Donor History |
Adenocarcinoma |
| Growth Properties |
Adherent ,colonies |
| Growth Conditions |
Culture medium: McCoys 5a ,w: 3.0 g/L Glucose ,w: stable Glutamine ,w: 2.0 mM Sodium pyruvate ,w: 2.2 g/L NaHCO3 (Cytion article number 820200a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: 1 x 10⁴ cells/cm² will result in a confluent monolayer within 7 days. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The Capan-2 cell line is a human pancreatic adenocarcinoma cell line first isolated from the pancreatic tumor tissue of a 56-year-old Caucasian male. It was derived from the metastatic site in the liver, indicating its origin from a secondary tumor which makes it particularly valuable for research on metastatic processes and pancreatic cancer biology. The cells exhibit epithelial morphology and have been utilized extensively to study pancreatic cancer, drug resistance, and tumor biology.
Capan-2 cells are known to express a mutated form of the Kirsten rat sarcoma viral oncogene homolog (KRAS), a common mutation in pancreatic cancer, making them a robust model for studying KRAS-driven tumorigenesis. Additionally, they are characterized by the expression of tumor suppressor gene p53 mutations and have been observed to exhibit chromosomal instabilities, which are critical features relevant to cancer progression and treatment response. This cell line has been used in numerous studies, including those evaluating chemotherapeutic efficacy, exploring molecular pathways of cancer progression, and developing targeted therapy strategies.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

